ALDX · Aldeyra Therapeutics, Inc.
$1.56
+0.00 (+0.00%)
At close · Aug 17
Market Cap
$94.11M
Shares
60.33M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $4,704,179 |
| Stephen G. Machatha | Ph.D. . Chief Development Officer | $1,452,142 |
| Michael Alfieri | Principal Financial Officer and Principal Accounting Officer | $245,963 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $3,931,645 |
| Stephen G. Machatha | Chief Development Officer | $1,688,381 |
| Bruce Greenberg | M.B.A. former Senior Vice President of Finance, Interim Chief Financial Officer | $1,217,546 |
| Michael Alfieri | Principal Financial Officer and Principal Accounting Officer | $111,650 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $3,684,651 |
| Stephen G. Machatha | Chief Development Officer | $1,593,108 |
| Bruce Greenberg | M.B.A. former Senior Vice President of Finance, Interim Chief Financial Officer | $974,067 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $2,858,490 |
| Stephen G. Machatha | Chief Development Officer | $2,565,216 |
| Bruce Greenberg | M.B.A. Senior Vice President of Finance, Interim Chief Financial Officer | $1,482,055 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $3,455,670 |
| Joshua Reed | Chief Financial Officer | $1,848,134 |
| Stephen G. Machatha | Chief Development Officer | $1,431,416 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $2,421,362 |
| Joshua Reed | Chief Financial Officer | $1,688,894 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $4,141,261 |
| Joshua Reed | Chief Financial Officer | $2,181,275 |
| David J. Clark | — | $1,971,610 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Todd C. Brady | M.D., Ph.D. President and Chief Executive Officer | $2,876,740 |
| Former Chief | Medical Officer | $1,206,138 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Darlene Deptula-Hicks | Chair of the audit committee of the Board | Appointed | 2026-06-10 |
| Darlene Deptula-Hicks | Class III director | Appointed | 2026-06-10 |
| Stephen G. Machatha, Ph.D. | Chief Development Officer | Resigned | 2025-12-31 |
| William (Chip) Clark | Class I director | Appointed | 2025-04-17 |
| Michael Alfieri | principal financial officer and principal accounting officer | Appointed | 2024-09-03 |
| Bruce Greenberg | Interim Chief Financial Officer | Appointed | 2022-04-28 |
| Bruce Greenberg | Vice President of Finance | Appointed | 2022-04-28 |
| Joshua Reed | Treasurer | Resigned | 2022-04-28 |
| Joshua Reed | Chief Financial Officer | Resigned | 2022-04-28 |
Key facts
CIK
1341235
CUSIP
01438T106
13F (30d)
108 filings
99 filers
Visit website
Investor relations